Etodolac dosage

Etodolac is a racemic acetic acid derivative with an intermediate half-life (Table 36-1). Etodolac does not undergo chiral inversion in the body. The dosage of etodolac is 200-400 mg three to four times daily. 

A colorimetric method for the analysis of etodolac has been reported which is based on the formation of colored complexes with p-dimethyl-aminobenzaldehyde in the presence of sulfuric acid and ferric chloride [19]. Absorbance measurements were made at 591.5 nm, and the method was found to be linear over the concentration range of 10 to 80 pg/mL. This method was used to determine etodolac in bulk powder and other dosage forms. 

A simple, sensitive, and reproducible fluorimetric method for the determination of etodolac in bulk powder or dosage forms has been reported [19]. The method involves measurement of the native fluorescence at a wavelength of 345 nm, when ethanolic solutions of the drug were excited at 235 nm. The calibration was found to be linear over the concentration range of 96 to 640 ng/mL. 

In 1986, the UK Drug Safety Research Unit at Southampton published a report on its prescription event monitoring study of etodolac (SEDA-13, 80). Etodolac was rated effective in only 56% of 9109 patients, and the Unit concluded that the average dosage used... 

There is little evidence to support clinically important differences with regard to the frequency of ulcers and upper GI complications among most available nonaspirin, nonselective NSAIDs (see Table 33-3) when used in equipotent anti-inflammatory dosages. However, the nonacetylated salicylates (e.g., salsalate) and newer NSAIDs (e.g., etodolac, nabumetone, and meloxicam) may be associated with a decreased incidence of GI toxicity. NSAIDs that selectively inhibit cyclooxygenase-2 (COX-2) decrease the incidence of gastroduodenal ulcers and related GI complications when compared to the nonselective NSAIDs. The use of buffered or enteric-coated aspirin confers no added protection from ulcer or GI complications. ... 

---